Onkologische Schwerpunktpraxis Bielefeld
Industry / private company
Location:
Bielefeld,
Germany (DE)
ISNI: 000000405581094
Pet positivity after 2 cycles of abvd is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study (2019)
Fuchs M, Goergen H, Kobe C, Kuhnert G, Hitz F, Greil R, Sasse S, et al.
Conference contribution
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial (2019)
Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, zu Eulenburg C, et al.
Journal article
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants (2017)
Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, et al.
Journal article